DTIL · Precision Biosciences Inc · Executive Compensation
$6.30
+0.05 (+0.80%)
At close · Oct 8
Return incl. dividend (before tax)
Market Cap
$174.58M
Shares
27.60M
Volume · Oct 7
162.52K
Avg daily vol (3M)
304.83K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Michael Amoroso | President, Chief Executive Officer and Director | $2,189,467 |
| Alex Kelly | Chief Financial Officer | $1,134,116 |
| Dario Scimeca | General Counsel and Secretary | $911,641 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Michael Amoroso | President, Chief Executive Officer and Director | $4,310,914 |
| Alex Kelly | Chief Financial Officer | $1,893,387 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Michael Amoroso | President, Chief Executive Officer and Director | $2,039,280 |
| Alex Kelly | Chief Financial Officer | $1,084,388 |
| Alan List | Chief Medical Officer | $909,970 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Michael Amoroso | President, Chief Executive Officer and Director | $4,368,115 |
| Alex Kelly | Chief Financial Officer | $2,378,839 |
| Dario Scimeca | General Counsel and Secretary | $1,509,813 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Michael Amoroso | President, Chief Executive Officer and Director | $5,984,939 |
| Alex Kelly | Chief Financial Officer | $3,319,324 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Matthew Kane | President and Chief Executive Officer | $1,836,601 |
| Christopher Heery | Chief Medical Officer | $1,313,380 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Christopher Heery | Chief Medical Officer | $2,181,845 |
| Matthew Kane | President and Chief Executive Officer | $2,166,460 |
| Dario Scimeca | General Counsel | $1,710,211 |
| David Thomson | Chief Operating Officer | $734,392 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Matthew Kane | President and Chief Executive Officer | $1,587,132 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Naresh Tanna | Chief Financial Officer | Appointed | 2026-07-27 |
| Mei Burris | principal accounting officer and Chief Accounting Officer | Appointed | 2026-07-27 |
| Alex Kelly | Chief Operating Officer | Appointed | 2026-07-27 |
| Geno Germano | Class I director | Appointed | 2026-05-26 |
| Melinda Brown | Class I director | Appointed | 2026-05-26 |
| Sam Wadsworth | Board of Directors | Resigned | 2025-01-29 |
| Alan List, M.D. | Chief Medical Officer | Retired | 2024-09-12 |
| Samuel Wadsworth, Ph.D. | Class II director | Appointed | 2024-06-10 |
| Stanley R. Frankel, M.D. | Class II director | Appointed | 2024-06-10 |
| Alex Kelly | principal accounting officer | Appointed | 2023-09-07 |
| Shane Barton | Vice President and Corporate Controller | Resigned | 2023-09-07 |
| Neil Leatherbury | Senior Vice President, Head of Chemistry, Manufacturing and Controls (CMC) | Appointed | 2023-02-24 |
| Dr. Raymond Schinazi | Board of Directors (as well as his roles as Chair of the Board's Nominating and Corporate Governance Committee and a member of t | Resigned | 2022-11-10 |
| Derek Jantz | Board | Resigned | 2022-09-02 |
| Jeff Smith | Chief Research Officer | Appointed | 2022-09-02 |